Orange Book product · Generic (ANDA)
IPRATROPIUM BROMIDE
IPRATROPIUM BROMIDE
At a glance
Feb 23, 2026
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Feb 23, 2026
4 mo ago
Today
Exclusivity ends · PC
Patent-challenge (180-day generic) exclusivity
Oct 13, 2026
in 4 mo
Pharmaceutical detail
Active ingredient
IPRATROPIUM BROMIDE
Strength
0.021MG/INH
Dosage form
AEROSOL, METERED
Route
INHALATION
TE code
AB
Application
ANDA 217953
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of IPRATROPIUM BROMIDE
- 2004ATROVENT HFABrand (NDA)
NDA 021527 · BOEHRINGER INGELHEIM
- 1995ATROVENTBrand (NDA)
NDA 020393 · BOEHRINGER INGELHEIM
- 1995ATROVENTBrand (NDA)
NDA 020394 · BOEHRINGER INGELHEIM
- 1993ATROVENTBrand (NDA)
NDA 020228 · BOEHRINGER INGELHEIM
- 1986ATROVENTBrand (NDA)
NDA 019085 · BOEHRINGER INGELHEIM
- 2025IPRATROPIUM BROMIDEGeneric (ANDA)
ANDA 217912 · LUPIN
- 2025IPRATROPIUM BROMIDEGeneric (ANDA)
ANDA 217886 · LUPIN
- 2025IPRATROPIUM BROMIDEGeneric (ANDA)
ANDA 219222 · RUBICON RESEARCH
- 2024IPRATROPIUM BROMIDEGeneric (ANDA)
ANDA 219221 · RUBICON RESEARCH
- 2022IPRATROPIUM BROMIDEGeneric (ANDA)
ANDA 215104 · AMNEAL
- 2022IPRATROPIUM BROMIDEGeneric (ANDA)
ANDA 215105 · AMNEAL
- 2017IPRATROPIUM BROMIDEGeneric (ANDA)
ANDA 207903 · SUN PHARM
Marketing exclusivity (1)
- PCPatent-challenge (180-day generic) exclusivity
Oct 13, 2026
in 4 mo
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
